BRAF and lung adenocarcinoma: Dabrafenib and trametinib are highly efficacious therapies in patients with <i>BRAF</i> V600E-mutated lung adenocarcinoma (LUAD), but they are occasionally associated with the development of hemophagocytic lymphohistiocytosis (HLH).